

Phylogica

Harnessing Biodiversity for Peptide Therapies



Life Science Investment Summit, 19 October 2011

Nick Woolf: CFO & VP Corporate Development

Introduction

- Biotech company offering leading peptide drug discovery services
- Based in Perth, Western Australia, and Oxford, UK
- Headcount of approx. 25 employees
- Assembled world class peptide drug discovery platform
- Based on world's most structurally diverse library of natural peptides

Investment Highlights

- Strategy for rapid revenue growth from fee-for-service alliances
- Since 2009, signed partnerships with Roche, AstraZeneca & Pfizer
- Positioned for cash flow sustainability in 2012/2013

Key Numbers

- 10 billion peptides in our proprietary libraries
- 3 partnerships with major Pharma companies
- 100 % estimated revenue growth in FY2012

Phylomer[®] Drug Discovery Platform

Unique Source of Bioactive “Peptides”



Advantages of Peptides vs. Other Biologic Classes

Peptides (protein fragments) have advantages over larger biologics


- can be delivered by more patient friendly routes – eg: intranasal
- can be made synthetically at low cost
- can penetrate cells and access intracellular targets due to smaller size

Intracellular interactions control critical pathways in most diseases but have generally proved intractable with larger biologics

Protein



Phylomer




Phylomers Derive from Parts of Biodiverse Proteins

- Encoded from >35 biodiverse bacterial genomes, environments like volcanic streams, geysers and deep sea vents
- Phylomer libraries contain several billion distinct peptides
- Pre-selected by evolution to allow survival, such as thermal stability
- Dominant intellectual property over entire drug class



Fully-Integrated Drug Discovery Platform



— Assembled a world-class ‘one-stop-shop’ integrated drug discovery platform


- Proprietary technologies for rapid screening of libraries against drug targets
- Network of academic and biotech collaborators with synergistic technology
- State-of-the-art infrastructure and laboratory automation technology

Low-Risk Business Model

Drug Discovery Alliances



Focus on Drug Discovery Reduces Risk



- Upfront fees and research funding provide immediate revenue stream
- Build long-term value through milestones and royalties
- Secure increasing share of down-stream value
- Fund co-development and in-house programmes from surplus cash flow

Partnerships with Top-10 Pharma

Roche



- Collaboration to discover cell-penetrating peptides in December 2009
- Successful completion of initial research objectives in February 2011
- Expanded to discover peptides that cross blood-brain barrier in May 2011

MedImmune (AstraZeneca)



- Collaboration to discover novel antibiotic peptides in August 2010
- Total deal value of up to US\$100M & royalties on worldwide sales

Pfizer



- Collaboration to discover novel peptide vaccines in December 2010
- Total deal value of up to US\$135M & royalties on worldwide sales

Robust Finances Supported by Revenue

—● FY2011 results in line with expectations

- Revenue of A\$2.5 million (+259% vs. FY2010)
- Net loss narrowed to A\$3.6 million (vs. A\$4.6 million)

—● Analysts estimate +100% revenue growth in FY2012

—● Net cash of A\$5.2 million at 30 June 2011

—● Positioned for cash flow sustainability in 2012/2013

Major Shareholders

- NAOS Asset Management: 10%
- Australian Heritage Group: 8%
- Ascent BioMedical Holdings: 5%
- Telethon Institute of Child Health Research: 5%
- Management: 5%

One-Year Share Price Performance (PYC.AX)

- Issued capital of 405 million shares

- Average daily volume (3 months) of 750k shares



Summary

- Assembled world-class peptide drug discovery platform
- Successfully validated 'Alliance Model' with three pharma partners
- Strong institutional shareholder base
- Anticipate rapid revenue growth based on current and prospective deals
- On track to achieve cash sustainability

Dr. Paul Watt
Chief Executive Officer
Tel: +61 8 9382 8888
Fax: +61 8 9382 1766
Mobile UK: +44 7775 682478
paulw@phylogica.com

Nick Woolf
CFO, VP Corporate Development
Tel: +61 8 9382 8888
Fax: +61 8 9382 1766
Mobile AUS: +61 417 986 005
nwoolf@phylogica.com



www.phylogica.com